{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-25-000058","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.419005+00:00","generated_at":"2026-05-20T18:27:04.772367+00:00","sec_items":["5.02","5.03","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Serina appoints ex-Karuna CMO Brannan to board; director Gross departs","bullets":["Appointed Dr. Stephen Brannan (former Karuna CMO) to board and Compensation Committee, effective May 22, 2025.","Brannan led clinical strategy for KarXT, first new schizophrenia mechanism in >30 years, key to Karuna's $14B BMS acquisition.","Remy Gross departed board effective May 22, 2025; no disagreement, stays as consultant.","Filed certificate of correction to Series A Preferred Stock to add conversion price adjustment reference."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-25-000058","json":"https://secwatch.observer/filing/0001708599-25-000058.json","markdown":"https://secwatch.observer/filing/0001708599-25-000058.md","text":"https://secwatch.observer/filing/0001708599-25-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000058/0001708599-25-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000058/ser-20250522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T18:27:04.772367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5a49a5b57","claim":"Remy Gross departed as Director at Serina Therapeutics, Inc..","evidence_excerpt":"The Company also announced the departure of Remy Gross from its Board of Directors effective May 22, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000058/0001708599-25-000058-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"daf6926ee3","claim":"Stephen Brannan was appointed as Director at Serina Therapeutics, Inc..","evidence_excerpt":"On May 22, 2025 , the Board of Directors of Serina Therapeutics, Inc. (the “Company”) appointed Dr. Stephen Brannan to the Company’s Board of Directors, effective May 22, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000058/0001708599-25-000058-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}